Form D · Biotechnology
Penderia Technologies, Inc.
Eugene, OR · CIK 0002022700
Offering snapshot reported May 9, 2024 · SEC filing
- Reported sold
- $65K Offering amount: $1M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 22, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 9, 2024 | Initial | $65,000 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-512790
SAFE (Simple Agreement for Future Equity)
Source: Form D, filed May 9, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Kenneth Gall | Director |
| Robert Guldberg | Director |
| Salil Karipott | Executive |
| Stephen Laffoon | Executive |
| Michael Mc Geehan | Executive |
| Keat Ghee Ong | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
6231 University Of Oregon
Eugene, OR, 97403
Eugene, OR, 97403